Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.

摘要

Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload [1]. Clinical trials have demonstrated the efficacy of deferasirox for up to 2 years of treatment in patients with myelodysplastic syndromes (MDS) [2,3]. The drug is able to reduce key indicators of total body iron levels (serum ferritin, liver iron concentration and toxic labile plasma iron) and has also demonstrated a good tolerability profile, which renders it a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy.